The scientific goals of the Experimental and Developmental (EDT) Program are to: 1) Discover and validate novel therapeutic targets;2) Identify new therapeutic agents and approaches, and 3) Conduct early phase translational clinical trials of novel therapies. The EDT Program is comprised of 25 members from two schools at the University of Texas Health Science Center at San Antonio (UTHSCSA) and one college at the University of Texas at San Antonio (UTSA). The EDT membership represents 11 departments and has been recruited from notable institutions including Harvard Medical School, MD Anderson Cancer Center and UT Southwestern. The EDT Program members have a wide range of expertise, from synthetic organic chemistry and structural biology, through lead identification and IND-enabling studies, obtaining an IND, to conducting clinical trials. These complementary areas of expertise provide the opportunities for cutting-edge translational research. Seven Program members are clinician scientists, physicians, or dentists who provide a strong translational focus to the program. The Co-Leaders, Drs. Weitman and Mooberry have complementary areas of expertise and interests to span the entire range of activities of the Program. In the past budget year, EDT members received a total of $2,150,045 of NCI funding (11 grants) and an additional $2,723,945 (15 grants) of other peer-reviewed cancer-related grant support. The EDT Program has 177 peer-reviewed cancer related publications of which 89 (50%) are intra-programmatic collaborations and 26 (15%) are inter-programmatic collaborations.
The Experimental and Developmental Therapeutics (EDT) Program takes the lead in the Cancer Therapy & Research Center's effort to develop and test new treatments for cancer. It is an integrated multidisciplinary collaborative effort between diverse disciplines of pre-clinical and clinical scientists, all of whom are focused on improving the treatment of cancer.
|Zanotto-Filho, Alfeu; Dashnamoorthy, Ravi; Loranc, Eva et al. (2016) Combined Gene Expression and RNAi Screening to Identify Alkylation Damage Survival Pathways from Fly to Human. PLoS One 11:e0153970|
|Newcomb, Lisa F; Thompson Jr, Ian M; Boyer, Hilary D et al. (2016) Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. J Urol 195:313-20|
|Ortiz, Carmen; Morales, Luisa; Sastre, Miguel et al. (2016) Cytotoxicity and Genotoxicity Assessment of Sandalwood Essential Oil in Human Breast Cell Lines MCF-7 and MCF-10A. Evid Based Complement Alternat Med 2016:3696232|
|Price, Douglas K; Chau, Cindy H; Till, Cathee et al. (2016) Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial. Cancer 122:2332-40|
|Zanotto-Filho, Alfeu; Masamsetti, V Pragathi; Loranc, Eva et al. (2016) Alkylating Agent-Induced NRF2 Blocks Endoplasmic Reticulum Stress-Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis. Mol Cancer Ther 15:3000-3014|
|Sareddy, Gangadhara R; Li, Xiaonan; Liu, Jinyou et al. (2016) Selective Estrogen Receptor Î² Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma. Sci Rep 6:24185|
|Sweeney, Shannon R; Kavanaugh, Arthur; Lodi, Alessia et al. (2016) Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis. RMD Open 2:e000289|
|Schenk, Jeannette M; Till, Cathee; Hsing, Ann W et al. (2016) Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial. Cancer Causes Control 27:175-82|
|Toledo, Rodrigo A; Qin, Yuejuan; Cheng, Zi-Ming et al. (2016) Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas. Clin Cancer Res 22:2301-10|
|Wu, Anqi; Dong, Qiaoxiang; Gao, Hui et al. (2016) Characterization of mammary epithelial stem/progenitor cells and their changes with aging in common marmosets. Sci Rep 6:32190|
Showing the most recent 10 out of 853 publications